Pediatric brain tumors rely on different metabolic “route” to fuel treatment resistance

Researchers found that these tumors’ metabolism differs from adult brain tumors, a key to understanding treatment resistance in this aggressive form of cancer

5:00 AM

Author | Anna Megdell

different cars from helicopter view on highways intersecting going all different ways seeing greenery and roads
Getty Images

Researchers at the University of Michigan Health Rogel Cancer Center are one step closer to understanding how pediatric DIPG tumors work. 

Diffuse intrinsic pontine glioma, or DIPG, is the most aggressive pediatric brain tumor and incredibly difficult to treat since surgery isn’t feasible and recurrence is likely after radiation. 

These tumors are often defined by the H3K27M driver histone mutation. 

Rogel researchers, led by Daniel Wahl, M.D., Ph.D., wanted to understand how this mutation affects DIPG tumor metabolism and influences radiation resistance.

“These questions pointed us straight to purine metabolism,” said Wahl, associate professor of radiation oncology and neurosurgery. 

The findings were published in Cancer & Metabolism.

Wahl’s team has previously explored how purines are metabolized in adult glioblastoma, including a clinical trial to see how blocking purine metabolism improves treatment success. 

Here, the team tried a similar method of inhibiting purine synthesis. 

While it worked well in DIPG cells, it was less impressive in animal models. 

Wahl explains that, unlike many adult glioblastomas, DIPG tumors seem to rely on two different routes to make purines. He likens it to a road with two on-ramps. 

“In adult GBMs, one of these on-ramps seems to be blocked, almost like it’s under construction. If you block the second on-ramp with a drug, it’s a real problem for the tumor. But in these pediatric brain tumors, both on-ramps appear to be wide open. So a drug that just blocks one of them doesn’t really slow down the DIPGs.” 

Although there isn’t a drug available to block this “second” on-ramp, Wahl was able, through genetic silencing, to stop purines from being made inside the cell. 

“When we did that, radiation worked great,” Wahl said. 

Erik Peterson, lead author and cancer biology graduate student agrees.

“A better understanding of how these tumors evade treatment means that we’re better equipped to develop new strategies to beat them at their own game and improve the outlook for kids with this disease.”

Next, the researchers want to build on these findings to better understand why pediatric DIPG tumors rely on a different route from adult tumors, and how they can develop therapies to block it. 

With this additional work, the research team is hopeful that they could make a dent in this disease for patients in the future. 

Additional authors: Peter Sajjakulnukit, PhD, Andrew J. Scott, PhD, Caleb Heaslip, Anthony Andren, Kari Wilder-Romans, Weihua Zhou, PhD, Sravya Palavalasa, MBBS, PhD, Navyateja Korimerla, PhD, Angelica Lin, Alexandra O’Brien, Ayesha Kothari, Zitong Zhao, Li Zhang, PhD, Meredith A. Morgan, PhD, Sriram Venneti, MD, PhD, Carl Koschmann, MD, Nada Jabado, MD, PhD, Costas A. Lyssiotis, PhD, Maria G. Castro, PhD

Funding: ChadTough Defeat DIPG Foundation, Alex’s Lemonade Stand, Rogel Cancer Center, 

Paper cited: “Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline glioma,” Cancer & Metabolism. DOI: 10.1186/s40170-024-00341-7

Live your healthiest life: Get tips from top experts weekly. Subscribe to the Health & Wellness newsletter by Health Lab

Headlines from the frontlines: The power of scientific discovery harnessed and delivered to your inbox every week. Subscribe to Health Lab’s Research & Innovation newsletter

Like Podcasts? Add the Michigan Medicine News Break on SpotifyApple Podcasts or anywhere you listen to podcasts.


More Articles About: Rogel Cancer Center Cancer (Oncology) Cancer Research Brain and Spine Brain Health Brain Tumors
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories blue cell and red cell merging on dark blue screen
Health Lab
New cellular therapy trials for brain tumors
Michigan Medicine experts discuss CAR T therapy, its use in other clinical trials at U-M and the new Phase I trials that started in March 2025.
xray brain images on repeat and person pointing with pointer
Health Lab
Re-purposed FDA-approved drug could help treat high-grade glioma
Avapritinib, an FDA-approved drug used to treat other types of cancer, also decreases aggressive gliomas in animal models and in an initial cohort of patients with high-grade glioma.
doctors pointing at screen
Health Lab
A dosimetry code ready for widespread use in software
Patients receiving radiation treatment for cancer from around the country now benefit from a University of Michigan-developed code that research clinicians developed.
cancer cell drawing in blue some yellow off white background
Health Lab
Histotripsy can help release HER2 from cancer tumor cells
A study demonstrates how histotripsy could stimulate the immune system to destroy a cancer through the release of tumor antigens.
older daughter hugging and kissing her mom outside with blue sky by a rock
Health Lab
After daughter’s brain surgery, mom sells art to raise money for cancer research 
Nearly four and half years after her daughter’s lifesaving surgery to remove a glioma, a Michigan artist continues to raise money towards research for the treatment of cancerous brain tumors by selling her work.
pink blue green floating medicine symbols
Health Lab
An emerging class of RNA fighting cancer, infectious and genetic diseases
Michigan Medicine's College of Pharmacy researchers have developed a promising new weapon in the war on cancer: small circular mRNA vaccines.